Janssen Pharmaceutical Dodges Off-Label Opioid Lawsuit

A California federal judge dismissed a false claims act lawsuit accusing Johnson & Johnson subsidiary Janssen of providing illegal incentives for the off-label use of its product, Olysio.

The complaint, which alleged that the company offered illegal kickbacks to doctors who prescribed its opioid products, came from a former Janssen sales representative.

The plaintiff claimed to have discovered “huge profit spreads” and that the drug was reimbursed by Medicare and Medicaid in an illegal marketing scheme.